Earlier treatment in adults with high lifetime risk of cardiovascular diseases: What prevention trials are feasible and could change clinical practice? Report of a National Heart, Lung, and Blood Institute (NHLBI) Workshop

• Main Authors: Ann Marie Navar (Author), Lawrence J. Fine (Author), Walter T. Ambrosius (Author), Arleen Brown (Author), Pamela S. Douglas (Author), Karen Johnson (Author), Amit V. Khera (Author), Donald Lloyd-Jones (Author), Erin D. Michos (Author), Mahasin Mujahid (Author), Daniel Muñoz (Author), Khurram Nasir (Author), Nicole Redmond (Author), Paul M Ridker (Author), Jennifer Robinson (Author), David Schopfer (Author), Deborah F. Tate (Author), Cora E. Lewis (Author)
• Format: Bog
• Udgivet: Elsevier, 2022-12-01T00:00:00Z.
• Fag: article
• Online adgang: Connect to this object online.

More than half of U.S. young adults have low ten-year but high lifetime risk of cardiovascular disease (CVD). Improving primary prevention in young adulthood may help reduce persistent CVD disparities and overall CVD morbidity and mortality. The National Heart, Lung, and Blood Institute (NHLBI) conv...